Autologous transplantation of CD133+ BM-derived stem cells as a therapeutic option for dilatative cardiomyopathy
- 1 January 2006
- journal article
- Published by Elsevier in Cytotherapy
- Vol. 8 (3) , 308-310
- https://doi.org/10.1080/14653240600735909
Abstract
We report the case of a 58-year-old man with end-stage non-ischemic cardiomyopathy. Baseline transthoracic echocardiography (TTE) and cardiac magnetic resonance (cMRI) revealed a markedly depressed left ventricle systolic function. He underwent autologous CD133+ BM-derived cell transplantation through a minimally invasive approach. During surgery 19 × 106 BM-derived stem cells were injected by the transepimyocardial route. Six months after the operation TTE and cMRI showed a clear improvement in left ventricular contractility.Keywords
This publication has 7 references indexed in Scilit:
- Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated CardiomyopathyCirculation, 2005
- Long-lasting improvement of myocardial perfusion and chronic refractory angina after autologous intramyocardial PBSC transplantationCytotherapy, 2005
- Intraoperative isolation and processing of BM-derived stem cellsCytotherapy, 2004
- Myoendothelial Differentiation of Human Umbilical Cord Blood–Derived Stem Cells in Ischemic Limb TissuesCirculation Research, 2003
- Autologous bone-marrow stem-cell transplantation for myocardial regenerationThe Lancet, 2003
- Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac functionNature Medicine, 2001
- The ISHAGE Guidelines for CD34+ Cell Determination by Flow CytometryJournal of Hematotherapy, 1996